BioNano Genomics Inc vs 8x8 Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while 8x8 Inc trades at $2.17 (market cap $309.09M). The key difference: 8x8 Inc is far larger — about 23.4× BioNano Genomics Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | EGHT | |
|---|---|---|
Market Cap | $13.20M | $309.09M |
Sector | Health | Technology |
52-Week High | $4.92 | $2.76 |
52-Week Low | $1.09 | $1.59 |
Enterprise Value | $15.81M | $586.76M |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
EGHT trades at $2.22, up 8.29% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent product innovations in AI routing and workforce management demonstrate growth potential, though high P/E ratio of 218 and negative net income require careful valuation assessment.
EGHT presents a turnaround story with improving earnings momentum and AI-driven product expansion, but faces significant execution risks amid high valuation multiples. The stock's technical strength contrasts with fundamental challenges, requiring balanced risk-reward evaluation for investors seeking growth opportunities in communications technology.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →